Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

J Cancer 2021; 12(13):3809-3818. doi:10.7150/jca.54527 This issue Cite

Research Paper

YTHDF2 inhibit the tumorigenicity of endometrial cancer via downregulating the expression of IRS1 methylated with m6A

Ling Hong#, Xiaowen Pu#, Haili Gan, lichun Weng, Qingliang Zheng✉

Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai 201204, China.
#These authors contributed equally to this work.

✉ Corresponding author: E-mail: 1701572edu.cn. Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, 2699 West Gaoke Road, Shanghai, 201204, P. R. China.

Citation:
Hong L, Pu X, Gan H, Weng l, Zheng Q. YTHDF2 inhibit the tumorigenicity of endometrial cancer via downregulating the expression of IRS1 methylated with m6A. J Cancer 2021; 12(13):3809-3818. doi:10.7150/jca.54527. https://www.jcancer.org/v12p3809.htm
Other styles

File import instruction

Abstract

Graphic abstract

RNA epigenetic modification take part in many biology processes, and the N6-methyladenosine (m6A) methylation of specific mRNAs in endometrial cancer (EC) tissues play a key role in regulating the tumorigenicity of EC, but the specific mechanism still unknown and need to be investigated in the future. Here, we found that m6A reader protein YTHDF2 expression was significantly upregulated in EC compare to tumor adjacent tissues, YTHDF2 was then identified to inhibit the proliferation and invasion of EC cell lines. Mechanistically, the m6A reader YTHDF2 bind the methylation sites of target transcripts IRS1 and promoted IRS1 mRNA degradation, consequently inhibiting the expression of IRS1 and inhibiting IRS1/AKT signaling pathway, finally inhibit the tumorigenicity of EC. Thus, we demonstrated that YTHDF2 inhibited the proliferation and invasion of EC via inhibiting IRS1 expression in m6A epigenetic way, which suggests a potential therapeutic target for EC.

Keywords: YTHDF2, IRS1, endometrial cancer, AKT signaling pathway, m6A modification

Citation styles

APA
Hong, L., Pu, X., Gan, H., Weng, l., Zheng, Q. (2021). YTHDF2 inhibit the tumorigenicity of endometrial cancer via downregulating the expression of IRS1 methylated with m6A. Journal of Cancer, 12(13), 3809-3818. https://doi.org/10.7150/jca.54527.

ACS
Hong, L.; Pu, X.; Gan, H.; Weng, l.; Zheng, Q. YTHDF2 inhibit the tumorigenicity of endometrial cancer via downregulating the expression of IRS1 methylated with m6A. J. Cancer 2021, 12 (13), 3809-3818. DOI: 10.7150/jca.54527.

NLM
Hong L, Pu X, Gan H, Weng l, Zheng Q. YTHDF2 inhibit the tumorigenicity of endometrial cancer via downregulating the expression of IRS1 methylated with m6A. J Cancer 2021; 12(13):3809-3818. doi:10.7150/jca.54527. https://www.jcancer.org/v12p3809.htm

CSE
Hong L, Pu X, Gan H, Weng l, Zheng Q. 2021. YTHDF2 inhibit the tumorigenicity of endometrial cancer via downregulating the expression of IRS1 methylated with m6A. J Cancer. 12(13):3809-3818.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use